ChemicalBook > Product Catalog >API >Circulatory system drugs >Antiarrhythmics Drugs >Quinidine

Quinidine

Quinidine Suppliers list
Company Name: Shenzhen Sendi Biotechnology Co.Ltd.
Tel: 0755-23311925 18102838259
Email: Abel@chembj.com
Products Intro: Product Name:Quinidine
CAS:56-54-2
Purity:99% Package:4800/KG
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Email: info@dakenchem.com
Products Intro: Product Name:Quinidine
CAS:56-54-2
Purity:99.00% Package:100g,500g,1KG,10KG,100KG
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: CAS:56-54-2
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Mainchem Co., Ltd.
Tel: +86-0592-6210733
Email: sales@mainchem.com
Products Intro: Product Name:Quinidine
CAS:56-54-2
Company Name: career henan chemical co
Tel: +86-371-86658258
Email: sales@coreychem.com
Products Intro: Product Name:Quinidine
CAS:56-54-2
Purity:98% Package:1KG;1USD

Lastest Price from Quinidine manufacturers

  • Quinidine
  • US $1.00 / KG
  • 2019-05-13
  • CAS:56-54-2
  • Min. Order: 1KG
  • Purity: 98%
  • Supply Ability: 1ton
Quinidine Basic information
Product Name:Quinidine
Synonyms:(8R,9S)-6'-Methoxycinchonan-9-ol;6-METHOXY-A-(5-VINYL-2-QUINUCLIDINYL)-4-QUINOLINE-METHANOL;CONCHININE;CONQUININE;B-QUININE;(+)-QUINIDINE;QUINIDINE;(+)-QUINDINE
CAS:56-54-2
MF:C20H24N2O2
MW:324.42
EINECS:200-279-0
Product Categories:chiral;Alkaloids;Alkoxyquinolines;Biochemistry;for Resolution of Acids;Optical Resolution;Quinoline Alkaloids;Quinolines;Synthetic Organic Chemistry;Intermediates & Fine Chemicals;Pharmaceuticals;Cinchona AlkaloidsMonovalent Ion Channels;Chiral Catalysts, Ligands, and Reagents;Other Sodium Channel Modulators;-;Privileged Ligands and Complexes;Sodium Channel Modulators;Chiral Reagents;Heterocycles;DURAQUIN
Mol File:56-54-2.mol
Quinidine Structure
Quinidine Chemical Properties
Melting point 168-172 °C(lit.)
alpha 256 º (c=1, EtOH)
Boiling point 462.75°C (rough estimate)
density 1.1294 (rough estimate)
refractive index 1.5700 (estimate)
storage temp. Store at -20°C
form Powder
pka5.4, 10.0(at 20℃)
color White to off-white
optical activity[α]20/D +265±5°, c = 0.8% in ethanol (dry matter)
Water Solubility 0.05 g/100 mL (20 ºC)
Sensitive Light Sensitive
Merck 14,8060
BRN 91866
Stability:Stable. Incompatible with strong oxidizing agents.
CAS DataBase Reference56-54-2(CAS DataBase Reference)
NIST Chemistry ReferenceQuinine(56-54-2)
EPA Substance Registry SystemCinchonan-9-ol, 6'-methoxy-, (9S)-(56-54-2)
Safety Information
Hazard Codes Xn
Risk Statements 22-20/21/22
Safety Statements 36-22
RIDADR UN 2811 6.1/PG 3
WGK Germany 3
RTECS VA4725000
8
TSCA Yes
HazardClass 6.1(b)
PackingGroup III
HS Code 29392000
Hazardous Substances Data56-54-2(Hazardous Substances Data)
ToxicityLD50 in rats (mg/kg): 30 i.v., 263 orally (Dietmann)
MSDS Information
Quinidine Usage And Synthesis
DescriptionQuinidine is a commonly used class I antiarrhythmic drug. It is a stereoisomer of quinine, originally derived from the bark of the cinchona tree. It exerts its antiarrhythmic effects on the heart by interacting with the electrophysiology mechanisms that cause arrhythmias to modify the abnormalities in impulse initiation and conduction. Quinidine depresses normal automaticity in cardiac fibers that may act as ectopic pacemakers causing arrhythmias. Quinidine also blocks the slowly inactivating, tetrodotoxin-sensitive Na current, the slow inward calcium current (ICa), the rapid (IKr) and slow (IKs) components of the delayed potassium rectifier current, the inward potassium rectifier current (IKI), the ATP-sensitive potassium channel (IKATP) and Ito.
Chemical Propertieswhite to light yellow crystal powde
UsesA dextrorotatory stereoisomer of Quinine. Antiarrhythmic (class IA). Antimalarial
Usesantiarrhythmic, antimalarial
UsesQuinidine occurs in cinchona bark to about0.25–0.3% and also in cuprea bark. It is present in quinine sulfate mother liquor. Itis formed by isomerization of quinine. Itis used in the prevention of certain cardiacarrhythmias.
DefinitionChEBI: A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.
Brand nameDuraquin (Warner Chilcott); Quinaglute (Berlex).
Biological FunctionsQuinidine is an alkaloid obtained from various species of Cinchona or its hybrids, from Remijia pedunculata, or from quinine. Quinidine is the dextrorotatory isomer of quinine.Quinidine (Quinidex) was one of the first clinically used antiarrhythmic agents. Because of the high incidence of ventricular proarrhythmia associated with its use and numerous other equally efficacious agents, quinidine is now used sparingly. Quinidine shares all of the pharmacological properties of quinine, including antimalarial, antipyretic, oxytocic, and skeletal muscle relaxant actions.
General DescriptionCrystals or white powder.
Air & Water ReactionsInsoluble in water.
HazardPoison.
Health HazardQuinidine is more potent than quinine in itsaction on the cardiovascular system. Overdosesmay cause lowering of blood pressure.Gastric effects are lower than quinine. Toxicityis lower relative to quinine; subcutaneouslethal dose in mice is 400 mg/kg against200 mg/kg for quinine.
Fire HazardFlash point data for Quinidine are not available. Quinidine is probably combustible.
Clinical UsePrimary indications for the use of quinidine include (1) abolition of premature complexes that have an atrial, A-V junctional, or ventricular origin; (2) restoration of normal sinus rhythm in atrial flutter and atrial fibrillation after controlling the ventricular rate with digitalis; (3) maintenance of normal sinus rhythm after electrical conversion of atrial arrhythmias; (4) prophylaxis against arrhythmias associated with electrical countershock; (5) termination of ventricular tachycardia; and (6) suppression of repetitive tachycardia associated with Wolff- Parkinson-White (WPW) syndrome.
Although quinidine often is successful in producing normal sinus rhythm, its administration in the presence of a rapid atrial rate (flutter and possibly atrial fibrillation) can lead to a further and dangerous increase in the ventricular rate secondary to inhibition of basal vagal tone upon the A-V node. For this reason, digitalis should be used before quinidine when one is attempting to convert atrial flutter or atrial fibrillation to normal sinus rhythm.
Side effectsThe most common adverse effects associated with quinidine administration are diarrhea (35%), upper gastrointestinal distress (25%), and light-headedness (15%). Other relatively common adverse effects include fatigue, palpitations, headache (each occurring with an incidence of 7%), anginalike pain, and rash. These adverse effects are generally dose related and reversible with cessation of therapy. In some patients, quinidine administration may bring on thrombocytopenia due to the formation of a plasma protein–quinidine complex that evokes a circulating antibody directed against the blood platelet. Although platelet counts return to normal on cessation of therapy, administration of quinidine or quinine at a later date can cause the reappearance of thrombocytopenia.
The cardiac toxicity of quinidine includes A-V and intraventricular block, ventricular tachyarrhythmias, and depression of myocardial contractility. Ventricular arrhythmia induced by quinidine leading to a loss of consciousness has been referred to as quinidine syncope. This devastating side effect is more common in women than in men and may occur at therapeutic or subtherapeutic plasma concentrations. Large doses of quinidine can produce a syndrome known as cinchonism, which is characterized by ringing in the ears, headache, nausea, visual disturbances or blurred vision, disturbed auditory acuity, and vertigo. Larger doses can produce confusion, delirium, hallucinations, or psychoses.Quinidine can decrease blood glucose concentrations, possibly by inducing insulin secretion.
Safety ProfilePoison by ingestion, subcutaneous, intravenous, intramuscular, and intraperitoneal routes. A skin irritant. Implicated in aplastic anemia. When heated to decomposition it emits toxic fumes of NOx.
Drug interactionsQuinidine can increase the plasma concentrations of digoxin, which may in turn lead to signs and symptoms of digitalis toxicity. Gastrointestinal, central nervous system (CNS), or cardiac toxicity associated with elevated digoxin concentrations may occur.Quinidine and digoxin can be administered concurrently; however, a downward adjustment in the digoxin dose may be required.
Drugs that have been associated with elevations in quinidine concentrations include acetazolamide, the antacids magnesium hydroxide and calcium carbonate, and the H2-receptor antagonist cimetidine. Cimetidine inhibits the hepatic metabolism of quinidine. Phenytoin, rifampin, and barbiturates increase the hepatic metabolism of quinidine and reduce its plasma concentrations.
Purification MethodsCrystallise it from *C6H6 or dry CHCl3/pet ether (b 40-60o), discarding the initial, oily crop of crystals. Dry it under vacuum at 100o over P2O5. It has been used as a chiral catalyst [Wynberg & Staring J Am Chem Soc 104 166 1982, J Org Chem 50 1977 1985]. [Beilstein 23 H 506, 23 I 164, 23 II 414, 23 III/IV 3261, 23/13 V 395.]
PrecautionsOne of the few absolute contraindications for quinidine is complete A-V block with an A-V pacemaker or idioventricular pacemaker; this may be suppressed by quinidine, leading to cardiac arrest.
Persons with congenital QT prolongation may develop torsades de pointes tachyarrhythmia and should not be exposed to quinidine.
Owing to the negative inotropic action of quinidine, it is contraindicated in congestive heart failure and hypotension. Digitalis intoxication and hyperkalemia can accentuate the depression of conduction caused by quinidine.
Myasthenia gravis can be aggravated severely by quinidine’s actions at the neuromuscular junction. The use of quinidine and quinine should be avoided in patients who previously showed evidence of quinidine- induced thrombocytopenia.
ReferencesWit, Andrew L. "The Effects of Quinidine on the Cellular Electrophysiology of the Heart: A Brief Review." Journal of Cardiovascular Electrophysiology 3.5(2010):316-322.
Alloway, J. A., and M. P. Salata. "Quinidine-induced rheumatic syndromes. " Seminars in Arthritis & Rheumatism 24.5(1995):315-322.
Nakano, J, and M. C. R. Jr. "Effect of quinidine on cardiovascular dynamics." Arch Int Pharmacodyn Ther 168.2(1967):400-416.
Quinidine Preparation Products And Raw materials
Preparation ProductsQUININE SULFATE
Tag:Quinidine(56-54-2) Related Product Information
quinidine-3-hydroxylase HYDROQUINIDINE HYDROCHLORIDE QUINIDINE [9-H3 ] QUINIDINE [9-H3] quinidine polygalacturonate Quinidine sulphate hydrate,Quinidine dihydrate sulfate salt,QUINIDINE SULFATE,QUINIDINE SULFATE SALT DIHYDRATE,QUINIDINE SULPHATE DIHYDRATE,QUINIDINE SULFATE DIHYDRATE,quinidine,hemisulfate,hydrat (9S)-6'-methoxycinchonan-9-ol monohydrochloride QUINIDINE, [9-3H] Quinidine monohydrate hydrochloride,QUINIDINE HYDROCHLORIDE,QUINIDINE HYDROCHLORIDE MONOHYDRATE N-BENZYLQUINIDINIUM CHLORIDE 3-HYDROXY QUINIDINE QUINIDINE CUPRIC SULFATE (9S)-6'-methoxycinchonan-9-ol dihydrochloride QUINIDINE BISULFATE,Quinidine bisulphate,quinidine,sulfate(1:1)(salt Quinidine VINYL PROPIONATE Methoxy QUINIDINE SULFATE,Quinidine sluphate,Quinidine hemisulfate